Compare HRB & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRB | BLCO |
|---|---|---|
| Founded | 1955 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Ophthalmic Goods |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.0B |
| IPO Year | N/A | 2022 |
| Metric | HRB | BLCO |
|---|---|---|
| Price | $39.75 | $17.05 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 2 | 14 |
| Target Price | ★ $55.00 | $17.31 |
| AVG Volume (30 Days) | ★ 1.4M | 349.3K |
| Earning Date | 02-03-2026 | 02-18-2026 |
| Dividend Yield | ★ 4.20% | N/A |
| EPS Growth | ★ 9.63 | N/A |
| EPS | ★ 4.50 | N/A |
| Revenue | $3,770,736,000.00 | ★ $4,976,000,000.00 |
| Revenue This Year | $4.28 | $8.06 |
| Revenue Next Year | $3.14 | $5.79 |
| P/E Ratio | $8.85 | ★ N/A |
| Revenue Growth | 4.15 | ★ 6.23 |
| 52 Week Low | $38.88 | $10.45 |
| 52 Week High | $64.62 | $18.14 |
| Indicator | HRB | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 30.86 | 49.52 |
| Support Level | $38.88 | $16.85 |
| Resistance Level | $45.24 | $17.54 |
| Average True Range (ATR) | 1.29 | 0.43 |
| MACD | -0.37 | -0.06 |
| Stochastic Oscillator | 13.99 | 48.78 |
H&R Block Inc provides income tax return preparation services, digital do-it-yourself tax solutions, and other services related to income tax preparation to the general public in the United States, Canada, and Australia. The company mainly prepares tax returns for customers within the United States through its company-owned offices, franchise locations, and online tax software. The vast majority of H&R Block's offices are located in the U.S. The company derives the majority of its total revenue from the U.S. assisted tax preparation fees. Revenue from franchise and product royalties and digital do-it-yourself tax solutions is also relatively.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.